Compared to patients with tumours negative for EGFR and/or HER3, individuals with tumours positive for both EGFR and HER3 (EGFR FISH+/HER3+) had a significantly higher OR (36.4 vs 9.9%, P=0.037) and a significantly longer TTP (7.7 vs 2.7 months, P=0.032), with a non significant trend toward longer survival (13.8 vs 10.1 months, P=0.27, Figure 3). Here, ERBB3 is linked to neoplasm.